Uncovering the burden of tuberculosis in Algeria: a retrospective analysis from 2019 to 2024

IF 1.8 3区 生物学 Q4 MICROBIOLOGY
Amina Zergui, Nacim Bouziani, Kawtar Fidjel, Choubaila Leksir, Yamina Merzouk, Fatima Hanane Chentouf, Imane Djaballi, Mebrouk Kihal
{"title":"Uncovering the burden of tuberculosis in Algeria: a retrospective analysis from 2019 to 2024","authors":"Amina Zergui,&nbsp;Nacim Bouziani,&nbsp;Kawtar Fidjel,&nbsp;Choubaila Leksir,&nbsp;Yamina Merzouk,&nbsp;Fatima Hanane Chentouf,&nbsp;Imane Djaballi,&nbsp;Mebrouk Kihal","doi":"10.1007/s10482-025-02096-7","DOIUrl":null,"url":null,"abstract":"<div><p>Tuberculosis (TB) remains a global health challenge, particularly in low- and middle-income countries. This retrospective study aimed to analyze the epidemiological patterns, clinical characteristics, and treatment outcomes of TB in Algeria. A total of 729 medical records from patients treated at a public health facility in Oran between January 2019 and June 2024 were reviewed. The study revealed a mean patient age of 35.7 years (SD ± 16.4), with cases ranging from 1 to 88 years. Males accounted for 55% of TB cases, maintaining a consistent predominance across the study period. TB manifested primarily in two forms: pulmonary TB (PTB) in 45% of cases and extrapulmonary TB (EPTB) in 50%, with a small proportion (5%) presenting both types. EPTB was more prevalent among females (55%) and pediatric patients, whereas PTB was more frequent in individuals over 40 years. Comorbidities were documented in 19% of patients, with diabetes (7.5%), hypertension (6.2%), and HIV (1.8%) being the most common, predominantly affecting those over 50 years. Diagnosis relied on microscopy (52%), radiology (45%), and culture (3%). Most patients (83%) were newly diagnosed, while 17% had relapsed. Treatment involved Category I (83%) and Category II (17%) regimens. Overall, treatment outcomes were favorable, with a 91% cure rate, 8% drug resistance, and mortality below 1%. Between 2019 and 2023, cure rates improved from 89 to 94%, while resistance declined from 10 to 6%. These findings provide valuable insights into TB trends in Algeria, guiding public health interventions for better disease control.</p></div>","PeriodicalId":50746,"journal":{"name":"Antonie Van Leeuwenhoek International Journal of General and Molecular Microbiology","volume":"118 6","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antonie Van Leeuwenhoek International Journal of General and Molecular Microbiology","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1007/s10482-025-02096-7","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis (TB) remains a global health challenge, particularly in low- and middle-income countries. This retrospective study aimed to analyze the epidemiological patterns, clinical characteristics, and treatment outcomes of TB in Algeria. A total of 729 medical records from patients treated at a public health facility in Oran between January 2019 and June 2024 were reviewed. The study revealed a mean patient age of 35.7 years (SD ± 16.4), with cases ranging from 1 to 88 years. Males accounted for 55% of TB cases, maintaining a consistent predominance across the study period. TB manifested primarily in two forms: pulmonary TB (PTB) in 45% of cases and extrapulmonary TB (EPTB) in 50%, with a small proportion (5%) presenting both types. EPTB was more prevalent among females (55%) and pediatric patients, whereas PTB was more frequent in individuals over 40 years. Comorbidities were documented in 19% of patients, with diabetes (7.5%), hypertension (6.2%), and HIV (1.8%) being the most common, predominantly affecting those over 50 years. Diagnosis relied on microscopy (52%), radiology (45%), and culture (3%). Most patients (83%) were newly diagnosed, while 17% had relapsed. Treatment involved Category I (83%) and Category II (17%) regimens. Overall, treatment outcomes were favorable, with a 91% cure rate, 8% drug resistance, and mortality below 1%. Between 2019 and 2023, cure rates improved from 89 to 94%, while resistance declined from 10 to 6%. These findings provide valuable insights into TB trends in Algeria, guiding public health interventions for better disease control.

揭示阿尔及利亚结核病负担:2019年至2024年的回顾性分析
结核病仍然是一项全球卫生挑战,特别是在低收入和中等收入国家。本回顾性研究旨在分析阿尔及利亚结核病的流行病学模式、临床特征和治疗结果。对2019年1月至2024年6月期间在奥兰一家公共卫生机构接受治疗的患者的729份医疗记录进行了审查。研究显示,患者平均年龄为35.7岁(SD±16.4),病例从1岁到88岁不等。男性占结核病病例的55%,在整个研究期间始终保持优势。结核病主要表现为两种形式:45%的病例为肺结核(PTB), 50%的病例为肺外结核(EPTB),一小部分(5%)同时出现两种类型。EPTB在女性(55%)和儿科患者中更为普遍,而PTB在40岁以上的个体中更为常见。19%的患者有合并症,其中糖尿病(7.5%)、高血压(6.2%)和艾滋病毒(1.8%)最为常见,主要影响50岁以上的患者。诊断依赖于显微镜(52%)、放射学(45%)和培养(3%)。大多数患者(83%)为新诊断,17%复发。治疗包括第一类(83%)和第二类(17%)方案。总体而言,治疗结果良好,治愈率为91%,耐药率为8%,死亡率低于1%。2019年至2023年期间,治愈率从89%提高到94%,而耐药性从10%下降到6%。这些发现为了解阿尔及利亚的结核病趋势提供了有价值的见解,指导公共卫生干预措施以更好地控制疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
11.50%
发文量
104
审稿时长
3 months
期刊介绍: Antonie van Leeuwenhoek publishes papers on fundamental and applied aspects of microbiology. Topics of particular interest include: taxonomy, structure & development; biochemistry & molecular biology; physiology & metabolic studies; genetics; ecological studies; especially molecular ecology; marine microbiology; medical microbiology; molecular biological aspects of microbial pathogenesis and bioinformatics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信